These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1972253)

  • 1. Prevention of hepatitis C virus infection in haemophiliacs.
    Lancet; 1990 Jun; 335(8703):1473-4. PubMed ID: 1972253
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of hepatitis C virus infection in haemophiliacs.
    Barbara JA; Contreras M
    Lancet; 1990 Jul; 336(8706):62-3. PubMed ID: 1973252
    [No Abstract]   [Full Text] [Related]  

  • 3. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis.
    Skidmore SJ; Pasi KJ; Mawson SJ; Williams MD; Hill FG
    J Med Virol; 1990 Jan; 30(1):50-2. PubMed ID: 2106006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short incubation non-A, non-B hepatitis transmitted by factor VIII concentrates in patients with congenital coagulation disorders: a preliminary report of an antigen/antibody system.
    Bamber M; Murray A; Kernoff PB; Thomas HC
    Med Lab Sci; 1981 Oct; 38(4):373-8. PubMed ID: 6799726
    [No Abstract]   [Full Text] [Related]  

  • 5. Addition of hepatitis-B immunoglobulin to clotting factor.
    Scaroni C; Cancellieri V; Carnelli V; Moroni GA; Angeli M
    Lancet; 1980 Sep; 2(8193):537-8. PubMed ID: 6105587
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapy-induced hepatitis risk in hemophilia patients].
    Schiller WG; Renger FG
    Z Arztl Fortbild (Jena); 1983; 77(19):807-10. PubMed ID: 6417919
    [No Abstract]   [Full Text] [Related]  

  • 7. Non-A, non-B hepatitis and heat-treated factor VIII concentrates.
    Preston FE; Hay CR; Dewar MS; Greaves M; Triger DR
    Lancet; 1985 Jul; 2(8448):213. PubMed ID: 2862396
    [No Abstract]   [Full Text] [Related]  

  • 8. Addition of hepatitis-B immunoglobulin to clotting factors.
    Smit Sibinga CT; Das PC; Nieweg HO
    Lancet; 1980 Sep; 2(8193):537. PubMed ID: 6105586
    [No Abstract]   [Full Text] [Related]  

  • 9. Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator Group.
    Mannucci PM; Schimpf K; Abe T; Aledort LM; Anderle K; Brettler DB; Hilgartner MW; Kernoff PB; Kunschak M; McMillan CW
    Transfusion; 1992 Feb; 32(2):134-8. PubMed ID: 1311876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C and pasteurised factor VIII and IX concentrates.
    Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
    Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute hepatitis non-A, non-B following administration of factor VIII concentrates.
    Norkrans G; Widell A; Teger-Nilsson AC; Kjellman H; Frösner G; Iwarson S
    Vox Sang; 1981 Sep; 41(3):129-33. PubMed ID: 6800131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune status of HIV and HCV negative haemophiliacs treated with intermediate-purity factor VIII concentrates.
    Funk M; Ebener U; Kreuz W; Ehrenforth S
    Lancet; 1993 Oct; 342(8876):933-4. PubMed ID: 7692198
    [No Abstract]   [Full Text] [Related]  

  • 13. Absence of hepatitis A after treatment with pasteurised factor VIII concentrates in children with haemophilia A and von Willebrand disease.
    Kreuz W; Klarmann D; Auerswald G; Auberger K; Gürtler L; Rabenau H; Doerr WD
    Lancet; 1993 Feb; 341(8842):446. PubMed ID: 8094219
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk of HCV infection in haemophiliacs treated with a dry-heated factor VIII concentrate.
    Kolho E; Ebeling F; Rasi V
    Thromb Haemost; 1992 Jun; 67(6):728. PubMed ID: 1509419
    [No Abstract]   [Full Text] [Related]  

  • 15. Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P) in von Willebrand disease and haemophilia A: a viewpoint by Eric Berntorp.
    Berntorp E
    Drugs; 2007; 67(10):1520. PubMed ID: 17600396
    [No Abstract]   [Full Text] [Related]  

  • 16. [Efficacy in viral inactivation of the concentrates of factor VIII and IX by the solvent/detergent procedure. Evaluation in patients with hemophilia].
    Guerois C; Parquet A; Vicariot M; Lecoeur FF; Maisonneuve P; Courouce AM; Dubois F; Laurian Y
    Presse Med; 1991 Jun; 20(25):1163-6. PubMed ID: 1830653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of transfusion-associated virus infections in hemophilic patients needing replacement therapy].
    Meili EO
    Beitr Infusionsther; 1989; 24():46-55. PubMed ID: 2481548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate.
    Schimpf K; Brackmann HH; Kreuz W; Kraus B; Haschke F; Schramm W; Moesseler J; Auerswald G; Sutor AH; Koehler K
    N Engl J Med; 1989 Oct; 321(17):1148-52. PubMed ID: 2507917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of hepatitis G viraemia and liver disease in haemophiliacs previously exposed to non-virus inactivated coagulation factor concentrates.
    Hanley JP; Jarvis LM; Hayes PC; Lee AJ; Simmonds P; Ludlam CA
    Thromb Haemost; 1998 Feb; 79(2):291-5. PubMed ID: 9493578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.
    Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML
    Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.